Replies to post #241142 on Biotech Values

[Whalatane]

PEN issued a statement pre open saying they were not in discussions with SWAV . Hard to see the benefit for SWAV in that combo besides economy of scale etc and retail investors would be furious over any deal less than $250 a share .
But maybe SWAV is " in play " now ...we'll see
Kiwi